<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460419</url>
  </required_header>
  <id_info>
    <org_study_id>2015029</org_study_id>
    <nct_id>NCT02460419</nct_id>
  </id_info>
  <brief_title>Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Shantou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomised, phase 3 study is to evaluate the survival benefit of
      maintenance capecitabine plus best supportive care versus best supportive care for metastatic
      nasopharyngeal carcinoma patients after disease controlled with TPC palliative chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Firstly diagnosed metastatic nasopharyngeal carcinoma patients will receive 4-6 cycles of
      palliative chemotherapy with taxol,cisplatin and capecitabine. After disease controlled, they
      will be randomly assigned to maintenance capecitabine plus best supportive care(BSC) or BSC
      alone. The primary end point is progression-free survival, the secondary end points are
      overall survival, duration of response, objective response rate, adverse effects and quality
      of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>maintenance capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maintenance capecitabine plus best supportive care(BSC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>best supportive care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best supportive care and following-up every 6-8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>maintenance capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best supportive care (BSC)</intervention_name>
    <description>Best supportive care and following-up every 6-8 weeks</description>
    <arm_group_label>maintenance capecitabine</arm_group_label>
    <arm_group_label>best supportive care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Firstly diagnosed metastatic nasopharyngeal carcinoma patients

          -  Disease controlled after 4-6 cycles of palliative chemotherapy with taxol,cisplatin
             and capecitabine

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Life expectation at least 12 weeks

          -  No systemic chemotherapy within 6 months, except for induction chemotherapy or
             concurrent chemotherapy

          -  With at least one measurable lesion

          -  Enough blood test

          -  Signed informed consent

        Exclusion Criteria:

          -  Sever heart disease

          -  HIV infection

          -  Sever infection

          -  Brain metastasis, except received radical therapy 6 months ago and stable in 4 weeks

          -  Allogeneic organ transplantation

          -  Malignancy other than nasopharyngeal carcinoma, except:cervical carcinoma in situ,
             cured basal cell carcinoma,bladder cancer of Ta,Tis or T1, or any cured cancer for at
             least 3 years

          -  Pregnancy or breast feeding

          -  Difficulty in swallowing

          -  Received other test drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Guo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weixiong Xia, MD</last_name>
    <phone>86-20-87343379</phone>
    <email>xiawx@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xing Lv, MD</last_name>
    <phone>86-20-87343359</phone>
    <email>lvxing@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SunYat-senU</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weixiong Xia, MD</last_name>
      <phone>86-20-87343380</phone>
      <email>xiawx@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xing Lv</last_name>
      <phone>86-20-87343636</phone>
      <email>lvxing@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jin Y, Shi YX, Cai XY, Xia XY, Cai YC, Cao Y, Zhang WD, Hu WH, Jiang WQ. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012 Oct;138(10):1717-25. Epub 2012 Jun 10. Erratum in: J Cancer Res Clin Oncol. 2015 Apr;141(4):767.</citation>
    <PMID>22684794</PMID>
  </reference>
  <reference>
    <citation>Chua DT, Yiu HH, Seetalarom K, Ng AW, Kurnianda J, Shotelersuk K, Krishnan G, Hong RL, Yang MH, Wang CH, Sze WK, Ng WT. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head Neck. 2012 Sep;34(9):1225-30. doi: 10.1002/hed.21884. Epub 2011 Nov 11.</citation>
    <PMID>22076785</PMID>
  </reference>
  <reference>
    <citation>Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW, Tay MH, Poon D, Tan EH. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer. 2008 Sep 15;113(6):1332-7. doi: 10.1002/cncr.23687.</citation>
    <PMID>18615622</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>XIANG YANQUN</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>metastasis</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

